Hemopericardium in a Sirolimus-Treated Renal Transplant Patient

Sirolimus is an immunosuppressant frequently prescribed to prevent graft-vs-host disease in renal transplant patients. Pericardial effusion is recognized as a rare and potentially lethal side effect of this medication. Hemopericardium, specifically, is an even rarer complication that has yet to be r...

Descripción completa

Detalles Bibliográficos
Autores principales: Groudan, Kevin, Sawalha, Khalid, Bhat, Anusha G, Eltanbedawi, Ahmed, Ambesh, Paurush
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458718/
https://www.ncbi.nlm.nih.gov/pubmed/32879829
http://dx.doi.org/10.7759/cureus.9508
_version_ 1783576253772595200
author Groudan, Kevin
Sawalha, Khalid
Bhat, Anusha G
Eltanbedawi, Ahmed
Ambesh, Paurush
author_facet Groudan, Kevin
Sawalha, Khalid
Bhat, Anusha G
Eltanbedawi, Ahmed
Ambesh, Paurush
author_sort Groudan, Kevin
collection PubMed
description Sirolimus is an immunosuppressant frequently prescribed to prevent graft-vs-host disease in renal transplant patients. Pericardial effusion is recognized as a rare and potentially lethal side effect of this medication. Hemopericardium, specifically, is an even rarer complication that has yet to be reported in the literature. We report the first case of sirolimus-induced hemopericardium in a renal transplant patient.
format Online
Article
Text
id pubmed-7458718
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-74587182020-09-01 Hemopericardium in a Sirolimus-Treated Renal Transplant Patient Groudan, Kevin Sawalha, Khalid Bhat, Anusha G Eltanbedawi, Ahmed Ambesh, Paurush Cureus Cardiology Sirolimus is an immunosuppressant frequently prescribed to prevent graft-vs-host disease in renal transplant patients. Pericardial effusion is recognized as a rare and potentially lethal side effect of this medication. Hemopericardium, specifically, is an even rarer complication that has yet to be reported in the literature. We report the first case of sirolimus-induced hemopericardium in a renal transplant patient. Cureus 2020-08-01 /pmc/articles/PMC7458718/ /pubmed/32879829 http://dx.doi.org/10.7759/cureus.9508 Text en Copyright © 2020, Groudan et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Cardiology
Groudan, Kevin
Sawalha, Khalid
Bhat, Anusha G
Eltanbedawi, Ahmed
Ambesh, Paurush
Hemopericardium in a Sirolimus-Treated Renal Transplant Patient
title Hemopericardium in a Sirolimus-Treated Renal Transplant Patient
title_full Hemopericardium in a Sirolimus-Treated Renal Transplant Patient
title_fullStr Hemopericardium in a Sirolimus-Treated Renal Transplant Patient
title_full_unstemmed Hemopericardium in a Sirolimus-Treated Renal Transplant Patient
title_short Hemopericardium in a Sirolimus-Treated Renal Transplant Patient
title_sort hemopericardium in a sirolimus-treated renal transplant patient
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458718/
https://www.ncbi.nlm.nih.gov/pubmed/32879829
http://dx.doi.org/10.7759/cureus.9508
work_keys_str_mv AT groudankevin hemopericardiuminasirolimustreatedrenaltransplantpatient
AT sawalhakhalid hemopericardiuminasirolimustreatedrenaltransplantpatient
AT bhatanushag hemopericardiuminasirolimustreatedrenaltransplantpatient
AT eltanbedawiahmed hemopericardiuminasirolimustreatedrenaltransplantpatient
AT ambeshpaurush hemopericardiuminasirolimustreatedrenaltransplantpatient

Ejemplares similares